Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

Sep 20, 2011, 06:28 ET from Reportlinker

NEW YORK, Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0617091/Post-Menopausal-Hormone-Replacement-Therapy-HRT---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Post-Menopausal Hormone Replacement Therapy (HRT) market. The report identifies the key trends shaping and driving the global Post-Menopausal Hormone Replacement Therapy (HRT) market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Menopausal Hormone Replacement Therapy (HRT) sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post-Menopausal Hormone Replacement Therapy (HRT) market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Menopausal Hormone Replacement Therapy (HRT) market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Post-Menopausal Hormone Replacement Therapy (HRT) market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Menopausal Hormone Replacement Therapy (HRT) market.

- Analysis of key recent licensing and partnership agreements in Post-Menopausal Hormone Replacement Therapy (HRT) market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Post-Menopausal Hormone Replacement Therapy (HRT) market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Menopausal Hormone Replacement Therapy (HRT) market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Post-Menopausal Hormone Replacement Therapy (HRT) market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Post- Menopause Therapeutics - Introduction 7

2.1 Overview 7

2.2 Epidemiology 7

2.2.1 Prevalence 7

2.2.2 Morbidity 8

2.2.3 Mortality 8

2.2.4 Quality of life 9

2.2.5 Pharmaco-economic Burden 9

2.3 Physiology 10

2.4 Signs and Symptoms 10

2.4.1 Vasomotor Symptoms 10

2.4.2 Neuropsychiatric Symptoms 10

2.4.3 Associated States 11

2.4.4 Other 11

2.5 Diagnosis 12

2.5.1 FSH Blood Level Measurement 12

2.5.2 Estrogen Levels 12

2.5.3 Other Ovarian Hormones 13

2.6 Treatment and Management Options 13

2.6.1 Post-menopausal HRT 14

2.6.2 Types of Post-Menopausal HRT 14

2.6.3 Management of Menopause-Related Symptoms with Post-Menopausal HRT 15

2.6.4 Side Effects of Post-Menopausal HRT 16

2.6.5 Risks Associated with Post-Menopausal HRT 16

2.7 Referral Pathway 17

2.8 GlobalData Pipeline Report Guidance 18

3 Post- Menopausal HRT - Market Characterization 19

3.1 Overview 19

3.2 Post-Menopausal HRT Market Size (2005–2010) – Global 20

3.3 Post-Menopausal HRT Market Forecast (2010–2018) – Global 21

3.4 Post-Menopausal HRT Market Size (2005–2010) – The US 22

3.5 Post-Menopausal HRT Market Forecast (2010–2018) – The US 23

3.6 Post-Menopausal HRT Market Size (2005–2010) – France 24

3.7 Post-Menopausal HRT Market Forecast (2010–2018) – France 25

3.8 Post-Menopausal HRT Market Size (2005–2010) – Germany 26

3.9 Post-Menopausal HRT Market Forecast (2010–2018) – Germany 27

3.10 Post-Menopausal HRT Market Size (2005–2010) – Italy 28

3.11 Post-Menopausal HRT Market Forecast (2010–2018) – Italy 29

3.12 Post-Menopausal HRT Market Size (2005–2010) – Spain 30

3.13 Post-Menopausal HRT Market Forecast (2010–2018) – Spain 31

3.14 Post-Menopausal HRT Market Size (2005–2010) – The UK 32

3.15 Post-Menopausal HRT Market Forecast (2010–2018) – The UK 33

3.16 Post-Menopausal HRT Market Size (2005–2010) – Japan 34

3.17 Post-Menopausal HRT Market Forecast (2010–2018) – Japan 35

3.18 Drivers and Barriers for the Post-Menopausal HRT Market 36

3.18.1 Drivers for the Post-Menopausal HRT Market 36

3.18.2 Restraints for the Post-Menopausal HRT Market 36

3.19 Opportunity and Unmet Need Analysis 37

3.20 Key Takeaway 38

4 Post- Menopausal HRT - Competitive Assessment 39

4.1 Overview 39

4.2 Strategic Competitor Assessment 39

4.3 Product Profiles for the Major Marketed Products in the Post-Menopausal HRT Market 40

4.3.1 Premarin (Conjugated estrogens) 40

4.3.2 Vagifem (estradiol vaginal tablets) 42

4.3.3 Femring (estradiol acetate vaginal ring) 44

4.3.4 Prempro (Conjugated estrogens/medroxyprogesterone acetate tablets) 45

4.4 Key Takeaway 47

5 Post- Menopausal HRT - Pipeline Assessment 48

5.1 Overview 48

5.2 Strategic Pipeline Assessment 48

5.3 Post-Menopausal HRT Pipeline – Pipeline by Phases of Development 48

5.3.1 Post-Menopausal HRT – Phase III Pipeline 48

5.3.2 Post-Menopausal HRT – Phase II Pipeline 48

5.3.3 Post-Menopausal HRT – Pre-Clinical Pipeline 49

5.3.4 Technology Trends Analytic Framework 49

5.4 Post-Menopausal HRT Market –Pipeline by Mechanism of Action 51

5.5 Post-Menopausal HRT – Promising Drugs under Clinical Development 51

5.6 Molecule Profile for Promising Drugs under Clinical Development 52

5.6.1 Aprela (Bazedoxifene/conjugated estrogen) 52

5.6.2 Vaginorm (0.5% Dehydroepiandrosterone) 53

5.7 Key Takeaway 53

6 Post- Menopausal HRT - Clinical Trials Mapping 54

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 54

6.2 Clinical Trials by Phase 55

6.3 Clinical Trials by Trial Status 56

6.4 Prominent Sponsors 57

6.5 Top Companies Participating in Post-Menopausal HRT Clinical Trials 59

7 Post- Menopausal HRT - Strategic Assessment 60

7.1 Key Events Impacting the Future Market 60

7.2 Post-Menopausal HRT: Implications for Future Market Competition 61

8 Post- Menopausal HRT - Future Players 62

8.1 Introduction 62

8.2 Company Profiles 62

8.2.1 Pfizer Inc. 62

8.2.2 Bayer AG 65

8.2.3 Paladin Labs, Inc. 66

8.3 Other Companies in Post-Menopausal HRT Therapeutics Market 67

9 Post-Menopausal HRT - Licensing and Partnership Deals 68

10 Post- Menopausal HRT - Appendix 69

10.1 Market Definitions 69

10.2 Abbreviations 69

10.3 Research Methodology 70

10.3.1 Coverage 70

10.3.2 Secondary Research 71

10.3.3 Forecasting 71

10.3.4 Primary Research 74

10.3.5 Expert Panel Validation 74

10.4 Contact Us 74

10.5 Disclaimer 74

10.6 Bibliography 75

List of Tables

Table 1: Effects of Oral HRT on Annual Incidence of Selected Disorders in Post-Menopausal Women 8

Table 2: Mortality by Post-Menopausal HRT Use 8

Table 3: FSH Blood Level Measurement 12

Table 4: Estrogen Blood Level Measurement 12

Table 5: Treatment and Management Options in Post-Menopause 13

Table 6: Post-Menopausal HRT Market, Global, Revenue ($m), 2005–2010 20

Table 7: Post-Menopausal HRT Market, Global, Forecast ($m), 2010–2018 21

Table 8: Post-Menopausal HRT Market, The US, Revenue ($m), 2005–2010 22

Table 9: Post-Menopausal HRT Market, The US, Forecasts ($m), 2010–2018 23

Table 10: Post-Menopausal HRT Market, France, Revenue ($m), 2005–2010 24

Table 11: Post-Menopausal HRT Market, France, Forecasts ($m), 2010–2018 25

Table 12: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010 26

Table 13: Post-Menopausal HRT Market, Germany, Forecasts ($m), 2010–2018 27

Table 14: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010 28

Table 15: Post-Menopausal HRT Market, Italy, Forecasts ($m), 2010–2018 29

Table 16: Post-Menopausal HRT Market, Spain, Revenue ($m), 2005–2010 30

Table 17: Post-Menopausal HRT Market, Spain, Forecasts ($m), 2010–2018 31

Table 18: Post-Menopausal HRT Market, the UK, Revenue ($m), 2005–2010 32

Table 19: Post-Menopausal HRT Market, the UK, Forecasts ($m), 2010–2018 33

Table 20: Post-Menopausal HRT Market, Japan, Revenue ($m), 2005–2010 34

Table 21: Post-Menopausal HRT Market, Japan, Forecasts ($m), 2010–2018 35

Table 22: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Premarin 41

Table 23: Mean Values and Comparisons between Active Treatment Groups and the Placebo Group for the Number of Flashes per Day 42

Table 24: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Vagifem 43

Table 25: Mean Change from Baseline to Week 12 in a Composite Score of Most Irritating Symptoms Compared to Placebo 43

Table 26: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Femring 44

Table 27: Mean Change from Baseline in the Number of Moderate to Severe Vasomotor Symptoms per Week 45

Table 28: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Prempro 46

Table 29: Mean Values and Comparisons between the Active Treatment Groups and the Placebo Group for the Number of Flashes per Day 46

Table 30: Post-Menopausal HRT, Phase III Pipeline, 2011 48

Table 31: Post-Menopausal HRT, Phase II Pipeline, 2011 48

Table 32: Post-Menopausal HRT , Pre-Clinical Pipeline, 2011 49

Table 33: Post-Menopausal HRT – Most Promising Drugs Under Clinical Development, 2011 51

Table 34: Post-Menopausal HRT, Clinical Trials by Country, 2011 54

Table 35: Post-Menopausal HRT - Clinical Trials by Phase, 2011 55

Table 36: Post-Menopausal HRT, Clinical Trials by Status (%), 2011 56

Table 37: Post-Menopausal HRT, Prominent Sponsors, 2011 58

Table 38: Post-Menopausal HRT, Top Companies Participating in Therapeutics Clinical Trials, 2011 59

Table 39: Pfizer Inc., Menopause Management, Pipeline, 2011 64

Table 40: Bayer AG, Menopausal Management, Pipeline, 2011 66

Table 41: Paladin Labs Inc., Menopausal Management, Pipeline, 2011 67

Table 42: Post-Menopausal HRT Market – Future Players, 2011 67

Table 43: Post-Menopausal HRT, Global, Deals, 2009-2011 68

List of Figures

Figure 1: The Stages of Reproductive Aging Workshop (STRAW) 7

Figure 2: Estradiol and FSH Levels During a Normal Menstrual Cycle and Menopause 10

Figure 3: Sign and Symptoms of Post-Menopause 11

Figure 4: Treatment Algorithm for Post-Menopausal HRT* 15

Figure 5: Side Effects of Post-Menopausal HRT 16

Figure 6: Referral Pathway 17

Figure 7: Post-Menopausal HRT Market, Global, Revenue ($m), 2005–2010 20

Figure 8: Post-Menopausal HRT Market, Global, Forecast ($m), 2010–2018 21

Figure 9: Post-Menopausal HRT Market, The US, Revenue ($m), 2005–2010 22

Figure 10: Post-Menopausal HRT Market, The US, Forecast ($m), 2010–2018 23

Figure 11: Post-Menopausal HRT Market, France, Revenue ($m), 2005–2010 24

Figure 12: Post-Menopausal HRT Market, France, Forecast ($m), 2010–2018 25

Figure 13: Post-Menopausal HRT Market, Germany, Revenue ($m), 2005–2010 26

Figure 14: Post-Menopausal HRT Market, Germany, Forecast ($m), 2010–2018 27

Figure 15: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010 28

Figure 16: Post-Menopausal HRT Market, Italy, Forecast ($m), 2010–2018 29

Figure 17: Post-Menopausal HRT Market, Spain, Revenue ($m), 2005–2010 30

Figure 18: Post-Menopausal HRT Market, Spain, Forecast ($m), 2010–2018 31

Figure 19: Post-Menopausal HRT Market, the UK, Revenue ($m), 2005–2010 32

Figure 20: Post-Menopausal HRT Market, the UK, Forecast ($m), 2010–2018 33

Figure 21: Post-Menopausal HRT Market, Japan, Revenue ($m), 2005–2010 34

Figure 22: Post-Menopausal HRT Market, Japan, Forecast ($m), 2010–2018 35

Figure 23: Opportunity and Unmet Need in the Post-Menopausal HRT Market, 2010 38

Figure 24: Post-Menopausal HRT, Strategic Competitor Assessment, 2010 40

Figure 25: Post-Menopausal HRT – Pipeline by Phase of Development, 2011 48

Figure 26: Post-Menopausal HRT, Technology Trends Analytics Framework, 2011 49

Figure 27: Post-Menopausal HRT, Technology Trends Analytics Framework, Description, 2011 50

Figure 28: Post-Menopausal HRT, Pipeline by Mechanism of Action (%), 2011 51

Figure 29: Molecular Structure of Dehydroepiandrosterone (DHEA) 53

Figure 30: Post-Menopausal HRT, Clinical Trials by Country, 2011 54

Figure 31: Post-Menopausal HRT, Clinical Trials by Phase (%), 2011 55

Figure 32: Post-Menopausal HRT, Clinical Trials by Status (%), 2011 56

Figure 33: Post-Menopausal HRT, Overall Sponsors (%), 2011 57

Figure 34: Post-Menopausal HRT, Prominent Sponsors (%), 2011 58

Figure 35: Post-Menopausal HRT, Top Companies Participating in Clinical Trials, 2011 59

Figure 36: Post-Menopausal HRT Market, Drivers and Restraints, 2011 60

Figure 37: Post-Menopausal HRT, Implications for Future Market Competition, 2011 61

Figure 38: Post-Menopausal HRT Market, Pipeline by Company, 2011 62

Figure 39: GlobalData Market Forecasting Model 73

Companies Mentioned

Pfizer Inc.

Bayer AG

Paladin Labs, Inc

To order this report:

Therapy Industry: Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

Therapy Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com